期刊文献+

EML4-ALK融合基因与非小细胞肺癌分子靶向治疗的研究现况 被引量:1

下载PDF
导出
摘要 肺癌是当今世界最常见的恶性肿瘤之一。据统计,每年新发肺癌患者中有大约85%为非小细胞肺癌,而其中又有70%的患者在确诊时已存在局部晚期或远处转移[1]。近年来随着对癌症发病机制的深入研究和分子生物学的发展,出现了以特定分子为靶点的抗肿瘤药物。针对EGFR19或21号外显子突变而开发的酪氨酸激酶抑制剂,
作者 孟凡宇 李印
出处 《临床肺科杂志》 2013年第5期907-909,共3页 Journal of Clinical Pulmonary Medicine
  • 相关文献

参考文献28

  • 1Jemal A, Center MM, Dcsantis C, et al. Global patterns of cancer incidence and mortality rates and trends[ J]. Cancer Epidemiol Bio- markers Prev, 2010,19 : 1893 - 1907.
  • 2Mok TS, Wu YL, Thongprasert S. Phase m, randomised, openla- bel, first-line study of gefitinib vs carboplatin/paclitaxel in clinical- ly selected patients with advanced nonsmall-cell lung cancer (IPASS) [J]. in ESMO Confe 2008, Stockholm.
  • 3Palmer RH, Vernersson E, Grabbe C, et al. Anaplastic lymphoma kinase: signaling in development and disease [ J ]. Biochem J, 2009,420:345 - 361.
  • 4Camidge DR, Bang Y, Kwak EL, et al. Progression-Free Survival (PFS) from a Phase 1 Study of Crizotinib (PF-02341066) in Pa- tients with ALK-Positive Non-Small Cell Lung Cancer (NSCLC) [J]. in ASCO, 2011, Chicago.
  • 5Crino L, Kim D, Riely GJ, et al. Initial phase II results with erizo- tinib in advanced ALK-positive non-small cell lung cancer (NSCLC) : Profile 1005, in Aseo, 2011, Chicago. Soda M, Choi YL, Enomoto M, et al. Identification of the transfor- ming EMIA-ALK fusion gene in non small cell lung cancer[ J]. Na- ture, 2007,448(7153): 561 -566.
  • 6Crino L, Kim D, Riely GJ, et al. Initial phase II results with crizo- tinib in advanced ALK-positive non-small cell lung cancer (NSCLC) : Profile 1005, in Asco, 2011, Chicago. Soda M, Choi YL, Enomoto M, et al. Identification of the transfor- ming EMIA-ALK fusion gene in non small cell lung cancer[ J]. Na- ture, 2007,448(7153): 561 -566.
  • 7Takeuehi K, Choi YL, Togashi Y, et al. KIF5B-ALK, a novel fu- sion oncokinase identified by an immunohistochemistry-based diag- nostic system for ALK-positive lung cancer [ J ]. Clin Cancer Res, 2009,15:3143 - 3149.
  • 8Koivunen JP, Mermel C, Zejnullahu K, et al. EML4. ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer[ J ]. Clin Cancer Res, 2008, 14(13) : 4275 -4283.
  • 9Pemer S, Wagner PL, Demichelis F, et al. EMIA-ALK fusion lung cancer : a rare acquired event [ J ]. Neoplasia, 2008,10:298 - 302.
  • 10Wang DW, Leung EL, So KK, et al. The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmok- ers with wild-type EGFR and KRAS[ J]. Cancer, 2009,115 : 1723 - 1733.

同被引文献11

引证文献1

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部